Literature DB >> 17008857

Hormonal, auxological and clinical follow-up in children with connatal HIV infection. Personal records.

L Titone1, M C Maggio, P Di Carlo, A Romano, S Teresi, E Guicciardino, M Saitta, A Liotta.   

Abstract

AIM: HIV infection and antiretroviral drugs have relevant endocrine implications, affecting growth and pubertal development. Moreover stature impairment cannot depend only on decreased hormonal secretion.
METHODS: We studied for 7 years growth, puberty, bone maturation, hormonal secretion [Growth Hormone (GH) basal and after stimulation with Clonidin and Insulin, Insulin-like Growth Factor 1 (IGF-1), Insulin-like Growth Factor Binding Protein 3 (IGFBP-3), FSH, LH- gonadic hormones axis, ACTH, Cortisol, TSH, fT4, T4, T3, anti-thyroid antibodies, Leptin] of 10 HIV-infected children.
RESULTS: In 3 patients stature was <-2 SDS in the first 2 years and in prepubertal age, with intervals of improved growth. The weight was >2 SDS in 6 children, <-2 SDS in 1 girl, while the other 3 patients had a weight <-2SDS only in the first 2 years of life. Height growth velocity was >10 degrees Centile all over the years of follow-up in 9 patients, while weight growth velocity was pathological in 5. Leptinemia showed higher levels at the beginning of follow up: 0.82-11.68 ng/L (M+/-DS: 3.29+/-4.15) than at the end of the study: 0.2-3 ng/L (M+/-DS: 1.65+/-1.01). Leptin levels showed a statistically significant correlation with CD4/CD8 count (P: 0.010; r: 0.916) and with the CDC stage (P: 0.006; r: 0.937), meaning a strong link to the severity of the disease.
CONCLUSIONS: A good clinical control of HIV infection can guarantee growth within physiological centile in most of HIV-infected children. Over all IGFBP-3 and IGF-1 are good markers of growth, more usable than GH.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17008857

Source DB:  PubMed          Journal:  Minerva Pediatr        ISSN: 0026-4946            Impact factor:   1.312


  1 in total

Review 1.  Personalized therapeutics: HIV treatment in adolescents.

Authors:  N Y Rakhmanina; E V Capparelli; J N van den Anker
Journal:  Clin Pharmacol Ther       Date:  2008-10-01       Impact factor: 6.875

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.